Description du projet
Un test biochimique pour le diagnostic de traumatismes crânio-cérébraux
Dans une salle d’urgence, les médecins parviennent à diagnostiquer une suspicion de traumatisme crânio-cérébral (TCC) en combinant des scanners CT et IRM ainsi qu’une évaluation neurologique. Le projet Medicortex, financé par l’UE, a mis au point une autre méthode de diagnostic des TCC, qui est rapide et facile à utiliser et réalisable sur le lieu de soins, offrant ainsi des résultats immédiats. Le test est fondé sur des biomarqueurs spécifiques des TCC qui peuvent être détectés dans des échantillons de salive et d’urine, et il présente un grand potentiel pour améliorer les résultats cliniques de millions de personnes souffrant de TCC dans le monde.
Objectif
Traumatic Brain Injury (TBI) is the leading cause of central nervous system impairment, over traumatic spinal cord injury. Mild and moderate TBI cases represent more than 90% of TBI injuries but are unfortunately the most difficult to accurately diagnose. Currently, standard TBI diagnostic tools are based on CT scans, MRI scans or cognitive evaluations which are not always sufficient accurate to correctly diagnose mild and moderate cases, putting the patient at risks (long-term consequences of untreated TBI include headache, dizziness, irritability, anxiety and depression).
Medicortex is an innovative point of care test based on novel glycan-based biomarkers. The Medicortex diagnostic kit is a cost-efficient, quick and reliable test based on specific biomarkers for the identification of TBI in both saliva and urine samples. We have protected the innovation with several patents.
Many biomarkers have been suggested for TBI but none has resulted in an approved test. We have already proven that our biomarker is strongly correlated with TBI, allowing us to address a TBI point of care (POC) diagnostics market that will exceed €2 billion annually.
We will sell the Medicortex TBI tests and envision a price to distributors of €25. We expect distributors to charge €50 to healthcare providers and make a margin of 50%. This will reduce the TBI diagnostics cost by a factor of 10-25x for healthcare systems as a single test can be charged to the patient for less than €100 instead of €1,000 for a CT scan or €2,500 for an MRI scan. Two distributors have confirmed they interest in a letter.
Our Founder Dr. Harel has many years of experience in the pharmaceutical and biotech industry. Our Medical Director Dr. Mårten Kvist is active in academia and our Head of R&D Dr. Lasse Välimaa has a track record in R&D of bioanalytical methods and medical diagnostics.
Champ scientifique
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
20520 TURKU
Finlande
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.